OR WAIT null SECS
© 2021 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Dana-Farber Cancer Institute
June 29, 2021
The impact of the COVID-19 pandemic on the utilization of newer targeted therapies for HER2-positive metastatic breast cancer and considerations regarding their adoption into clinical practice based on the availability of vaccines.
The rationale for treating metastatic breast cancer with a dual HER2-targeted therapy approach.
June 22, 2021
Ian E Krop, MD, PhD, elaborates on which treatment settings are most appropriate to use HER2-targeted therapies in to manage metastatic breast cancer.
Considerations regarding how to best integrate newer targeted therapies available for HER2-positive metastatic breast cancer [MBC] into clinical practice.